Skip to main content
. 2020 Feb 12;38(6):1064–1071. doi: 10.1097/HJH.0000000000002390

TABLE 1.

Baseline characteristics according to quartiles of digital pulse propagation index

Quartile 1 Quartile 2 Quartile 3 Quartile 4
Full cohort <5.47 m/s 5.47–5.81 m/s 5.81–6.20 m/s >6.20 m/s P value
Participants, n 5487 1371 1372 1372 1372
DPPI (mean over 15 min) 5.81 [5.47–6.20] 5.22 [5.11–5.36] 5.64 [5.56–5.72] 5.98 [5.89–6.08] 6.55 [6.34–6.90]
Men (%) 50.6 19.8 47.9 65.2 69.8 <0.001
Age (years) 52.3 ± 11.8 47.1 ± 10.3 49.7 ± 11.1 52.9 ± 11.3 59.4 ± 11.0 <0.001
Waist circumference (cm) 91.9 ± 12.6 86.3 ± 12.6 89.8 ± 11.7 93.9 ± 11.5 97.4 ± 11.8 <0.001
Length (m) 1.73 ± 0.09 1.68 ± 0.08 1.73 ± 0.09 1.76 ± 0.09 1.75 ± 0.09 <0.001
Race (%) <0.001
 White 96.1 94.3 95.8 97.1 97.1
 Black 1.0 1.0 0.8 0.6 1.4
 Asian 1.9 3.3 2.2 1.0 0.9
 Other 1.1 1.4 1.2 1.3 0.6
Family history of CVD (%) 48.4 45.0 48.4 50.7 49.3 <0.001
History of CVD (%) 6 3.3 4.1 6.4 10.2 <0.001
SBP (mmHg) 125.5 ± 18.3 115.5 ± 14.8 122.7 ± 16.3 127.0 ± 16.0 136.7 ± 19.2 <0.001
DBP (mmHg) 73.4 ± 9.1 67.0 ± 7.2 71.6 ± 7.5 75.1 ± 7.8 79.7 ± 9.0 <0.001
MAP (mmHg) 92.2 ± 12.3 84.4 ± 9.6 90.0 ± 10.6 93.8 ± 10.3 100.6 ± 12.4 <0.001
Pulse pressure (mmHg) 52.2 ± 13.0 48.5 ± 11.2 51.1 ± 12.5 52.2 ± 12.2 56.9 ± 14.3 <0.001
Heart rate (bpm) 68.4 ± 10.0 65.0 ± 8.5 67.2 ± 9.5 69.3 ± 9.8 72.3 ± 10.6 <0.001
Use of AHD (%) 20.9 14.1 16.2 19.9 32.7 <0.001
Smoking (%) <0.001
 Never 29.6 37.6 32.9 28.9 20.0
 Former 41.8 39.2 40.7 41.7 47.2
 Current 27.3 21.7 26.3 29.4 32.8
Alcohol use (%) <0.001
 None/hardly ever 23.0 25.5 22.7 20.8 23.4
 1–4/month 15.8 18.7 17.0 13.9 13.8
 2–7/week 35.2 37.2 35.2 36.2 32.7
 1–3/day 20.2 15.5 21.0 22.5 22.2
 >3/day 5.2 2.6 4.1 6.6 7.8
Total cholesterol (mmol/l) 5.42 ± 1.0 5.1 ± 1.0 5.39 ± 1.05 5.53 ± 1.05 5.59 ± 1.04 <0.001
HDL cholesterol (mmol/l) 1.22 (1.04–1.43) 1.33 (1.15–1.54) 1.25 (1.06–1.47) 1.17 (1.00–1.38) 1.14 (0.97–1.35) <0.001
Triglycerides (mmol/l) 1.10 (0.81–1.58) 0.90 (0.67–1.28) 1.06 (0.77–1.50) 1.22 (0.90–1.72) 1.30 (0.93–1.88) <0.001
Use of LLD (%) 8.9 5.9 7.1 8.6 14.1 <0.001
History of diabetes mellitus (%) 2.4 1.3 1.9 2.1 4.3 <0.001
Serum glucose (mmol/l) 4.93 ± 0.92 4.72 ± 0.81 4.88 ± 0.91 4.94 ± 0.76 5.17 ± 1.10 <0.001
Serum kreatinine (μmol/l) 73.7 ± 19.8 68.5 ± 13.5 72.6 ± 18.98 75.1 ± 15.2 78.6 ± 27.3 <0.001
eGFR (CKD-EPI) 93.3 ± 15.8 96.5 ± 14.7 95.4 ± 15.3 93.7 ± 14.9 87.7 ± 74.5 <0.001
Urinary sodium excretion 145 ± 54 134.3 ± 48.0 143.1 ± 51.8 151.5 ± 56.0 152.6 ± 59.3 <0.001
Urinary albumin excretion 8.60 [6.06–15.1] 7.09 [5.49–10.83] 8.16 [5.95–13.3] 9.11 [6.37–14.8] 11.28 [7.06–26.92] <0.001

Data presented as mean ± SD, or median [IQR] or percentage of the population for normally, skewed, or nominal data, respectively. Differences were tested using analysis of variance (ANOVA), or Kruskal–Wallis tests for continuous data and with χ2 tests for categorical data. AHD, antihypertensive drugs; CKD-EPI, Chronic Kidney Disease-Epidemiology collaboration; CVD, cardiovascular disease; DBP, diastolic blood pressure; DPPI, digital pulse propagation index; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LLD, lipid lowering drugs; MAP, mean arterial pressure.